NEOPLASMS IN ACROMEGALY

Cover Page

Cite item

Abstract

Acromegaly is a  rare disease with increased growth hormone secretion most often caused by pituitary adenoma. Not adequately treated acromegaly may lead to early death related to increased rates of acute cardiovascular events, sleep apnea, metabolic disorders and malignancies. Prevalence of malignancies in acromegaly is in the range of 4.5 to 25%, with some specifics in their pathogenesis, and their proportion as mortality cause is 9 to 50%. Overall and cancer-related mortality in acromegaly are associated with activity of the disease. There is a direct correlation between high levels of insulin-like growth factor 1 and the risk of malignancies. The most common types of cancer in patients with acromegaly are colorectal (1 to 20%) and thyroid cancer (7.8 to 11%). This review of literature describes the results of epidemiological studies on malignancies and some aspects of their pathogenesis in patients with acromegaly.

About the authors

I. D. Chikh

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: trigolosova_ira@mail.ru
MD, Chief of Department of Therapeutic Endocrinology Russian Federation

I. V. Trigolosova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: trigolosova_ira@mail.ru
MD, PhD, Senior Research Fellow, Department of Therapeutic Endocrinology Russian Federation

A. V. Dreval'

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: trigolosova_ira@mail.ru
MD, PhD, Professor, Head of Department of Therapeutic Endocrinology; Chief of Chair of Endocrinology, Postgraduate Training Faculty Russian Federation

A. V. Trigolosov

N.N. Blokhin Russian Cancer Research Center; 24 Kashirskoe shosse, Moscow, 115478, Russian Federation

Email: trigolosova_ira@mail.ru
MD, PhD, Senior Research Fellow, Department of Radiosurgery Russian Federation

References

  1. Vilar L, Naves LA, Costa SS, Abdalla LF, Coel-ho CE, Casulari LA. Increase of classic and non-classic cardiovascular risk factors in patients with acromegaly. Endocr Pract. 2007;13(4): 363–72. doi: 10.4158/EP.13.4.363.
  2. Rodrigues MP, Naves LA, Casulari LA, Silva CA, Araújo RR, Viegas CA. Using clinical data to predict sleep hypoxemia in patients with acromegaly. Arq Neuropsiquiatr. 2007;65(2A):234–9. doi: http://dx.doi.org/10.1590/S0004-282X2007000200009.
  3. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 update. Endocr Pract. 2011;17 Suppl 4:1–44.
  4. Stewart PM, Sherlock M. Mortality and pituitary disease. Ann Endocrinol (Paris). 2012;73(2): 81–2. doi: 10.1016/j.ando.2012.03.026.
  5. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Co-lao A, Terzolo M; Italian Study Group of Acromegaly. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2): 189–98. doi: 10.1530/EJE-12-0084.
  6. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1): 61–7. doi: 10.1210/jc.2007-1191.
  7. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3): 301–42. doi: 10.1210/er.2009-0033.
  8. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39(153): 1–16.
  9. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008;9(1): 41–58. doi: 10.1007/s11154-007-9063-z.
  10. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26(4): 481–512. doi: 10.1111/j.1365-2265.1987.tb00805.x.
  11. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223(4): 327–35. doi: 10.1111/j.0954-6820.1988.tb15881.x.
  12. Etxabe J, Gaztambide P, Latorre P, Vazquez JA. Acromegaly: an epidemilogical study. J Endocrinol Invest. 1993;16(3): 181–7. doi: 10.1007/ BF03344942.
  13. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86(5): 293–9. doi: http://dx. doi.org/293-299.
  14. Rajasoorya C, Holdaway IM, Wright-son P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survivial in acromegaly. Clin Endocrinol (Oxf). 1994;41(1): 95–102. doi: 10.1111/j.1365-2265.1994.tb03789.x.
  15. Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(10): 3419–26. doi: 10.1210/ jcem.83.10.5222.
  16. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8): 2730–4. doi: 10.1210/jcem.83.8.5007.
  17. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after trans-sphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58(1): 86–91. doi: 10.1046/j.1365-2265.2003.01679.x.
  18. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89(4): 1613–7. doi: 10.1210/jc.2003-031584.
  19. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2): 667–74. doi: 10.1210/jc.2003-031199.
  20. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, Löyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7): 4081–6. doi: 10.1210/jc.2004-1381.
  21. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398. doi: 10.1155/2012/540398.
  22. Webb SM, Casanueva F, Wass JA. Onco-logical complications of excess GH in ac-romegaly. Pituitary. 2002;5(1): 21–5. doi: 10.1023/A:1022149300972.
  23. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jer-vis P, Roldan P, Mendoza V, López-Félix B, Guin-to G. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12): 4438–46. doi: 10.1210/jc.2014-2670.
  24. Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008;55(1): 67–71. doi: http://doi. org/10.1507/endocrj.K07E-010.
  25. Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T. Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. 2014;45(1): 114–21. doi: 10.1007/s12020-013-9981-3.
  26. Mustacchi P, Shimkin MB. Occurrence of cancer in acromegaly and in hypopituitarism. Cancer. 1957;10(1): 100–4. doi: 10.1002/1097-0142(195701/02)10:13.0.CO;2-V.
  27. Klein I, Parveen G, Gavaler JS, Vanthiel DH. Colonic polyps in patients with acromegaly. Ann Intern Med. 1982;97(1): 27–30. doi: 10.7326/0003-4819-97-1-27.
  28. Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin En-docrinol (Oxf). 1990;32(1): 65–71. doi: 10.1111/j.1365-2265.1990.tb03751.x.
  29. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer. 1991;68(8): 1673–7. doi: 10.1002/1097-0142(19911015)68: 83.0.CO;2-0.
  30. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5): 395–400. doi: 10.1023/A:1015713732717.
  31. Ritchie CM, Atkinson AB, Kennedy AL, Ly-ons AR, Gordon DS, Fannin T, Hadden DR. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J. 1990;59(1): 55–62.
  32. Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol (Oxf). 1997;47(3): 323–7.doi: 10.1046/j.1365-2265.1997.2561053.x.
  33. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998;49(4): 441–5. doi: 10.1046/j.1365-2265.1998.00536.x.
  34. Mestron A, Webb SM, Astorga R, Benito P, Cat-ala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4): 439–46. doi: 10.1530/eje.0.1510439.
  35. Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, Rivera J, Caspar-Bell G, Serri O. Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf). 2013;79(1): 79–85. doi: 10.1111/cen.12112.
  36. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1): 102–52. doi: 10.1210/ er.2002-0022.
  37. Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly – meta-analysis and systematic review. PLoS One. 2014;9(2):e88787. doi: 10.1371/journal.pone.0088787.
  38. Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P. Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem. 2010;285(9): 6563–72. doi: 10.1074/jbc. M109.097410.
  39. Jenkins PJ. Acromegaly and cancer. Horm Res. 2004;62 Suppl 1:108–15. doi: 10.1159/000080768.
  40. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Cop-pola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003;63(22): 7708–16.
  41. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28(1): 20–47. doi: 10.1210/er.2006-0001.
  42. Bradley LM, Gierthy JF, Pentecost BT. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line. J Steroid Biochem Mol Biol. 2008;109(1–2): 185–96. doi: 10.1016/j.jsbmb.2007.10.006.
  43. Lois K, Bukowczan J, Perros P, Jones S, Gunn M, James RA. The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary. 2015;18(4): 568–74. doi: 10.1007/s11102-014-0586-5.
  44. Pines A, Rozen P, Ron E, Gilat T. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol. 1985;80(4): 266–9.
  45. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med. 1991;151(8): 1629–32. doi: 10.1001/archinte.1991.00400080113022.
  46. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA, Besser M. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf). 1997;47(1): 17–22. doi: 10.1046/j.1365-2265.1997.1911029.x.
  47. Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pi-vonello R, Vitale G, Scillitani A, Attanasio R, Cecconi E, Daffara F, Gaia E, Martino E, Lombardi G, Angeli A, Colao A. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab. 2005;90(1): 84–90. doi: 10.1210/jc.2004-0240.
  48. Yamamoto M, Fukuoka H, Iguchi G, Matsumoto R, Takahashi M, Nishizawa H, Suda K, Bando H, Takahashi Y. The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary. 2015;18(3): 343–51. doi: 10.1007/s11102-014-0580-y.
  49. Ladas SD, Thalassinos NC, Ioannides G, Rap-tis SA. Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol (Oxf). 1994;41(5): 597–601. doi: 10.1111/j.1365-2265.1994.tb01824.x.
  50. Ortego J, Vega B, Sampedro J, Escalada J, Boixeda D, Varela C. Neoplastic colonic polyps in acromegaly. Horm Metab Res. 1994;26(12): 609–10. doi: 10.1055/s-2007-1001769.
  51. Renehan AG, Bhaskar P, Painter JE, O'Dwyer ST, Haboubi N, Varma J, Ball SG, Shalet SM. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85(9): 3417–24. doi: 10.1210/ jcem.85.9.6775.
  52. Rokkas T, Pistiolas D, Sechopoulos P, Mar-gantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008;14(22): 3484–9. doi: 10.3748/WJG.14.3484.
  53. Олейник ОВ, Молитвословова НН. Потенциальные предикторы и частота выявления новообразований щитовидной железы и желудочно-кишечного тракта у пациентов с акромегалией. Проблемы эндокринологии. 2015;61(2): 4–7. doi: 10.14341/probl20156124-7.
  54. Lincoln DT, Kaiser HE, Raju GP, Waters MJ. Growth hormone and colorectal carcinoma: localization of receptors. In Vivo. 2000;14(1): 41–9.
  55. Singh P, Rubin N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology. 1993;105(4): 1218–37. doi: http://dx.doi. org/10.1016/0016-5085(93)90971-E.
  56. Garrouste FL, Remacle-Bonnet MM, Lehmann MM, Marvaldi JL, Pommier GJ. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells. Endocrinology. 1997;138(5): 2021–32. doi: 10.1210/endo.138.5.5100.
  57. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Cop-pola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003;63(22): 7708–16.
  58. Jenkins PJ. Cancers associated with acromegaly. Neuroendocrinology. 2006;83(3–4): 218–23. doi: 10.1159/000095531.
  59. Cats A, Dullaart RP, Kleibeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ, de Vries EG. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56(3): 523–6.
  60. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res. 1989;80(1): 51–8. doi: 10.1111/j.1349-7006.1989.tb02244.x.
  61. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6(2): 164–79.
  62. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94(13): 972–80. doi: 10.1093/ jnci/94.13.972.
  63. Colao A, Pivonello R, Auriemma RS, Galdiero M, Ferone D, Minuto F, Marzullo P, Lombardi G. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab. 2007;92(10): 3854–60. doi: 10.1210/jc.2006-2551.
  64. Melmed S, Casanueva FF, Klibanski A, Bron-stein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3): 294–302. doi: 10.1007/s11102-012-0420-x.
  65. Jenkins PJ, Frajese V, Jones AM, Camacho-Hub-ner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP, Besser GM. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85(9): 3218–21. doi: 10.1210/jcem.85.9.6806.
  66. Anderson JC, Shaw RD. Update on colon cancer screening: recent advances and observations in colorectal cancer screening. Curr Gas-troenterol Rep. 2014;16(9): 403. doi: 10.1007/ s11894-014-0403-3.
  67. Cairns SR, Scholefield JH, Steele RJ, Dun-lop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5): 666–89. doi: 10.1136/gut.2009.179804.
  68. Eulenburg A. Реальная энциклопедия практической медицины. В 17 томах. Пер. с нем. СПб.: Практическая медицина; 1909. Том 1. с. 200.
  69. Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A; Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25(3): 240–5. doi: 10.1007/BF03343997.
  70. Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9(8): 791–6. doi: 10.1089/thy.1999.9.791.
  71. Herrmann BL, Baumann H, Janssen OE, Görg-es R, Schmid KW, Mann K. Impact of disease activity on thyroid diseases in patients with ac-romegaly: basal evaluation and follow-up. Exp Clin Endocrinol Diabetes. 2004;112(5): 225–30. doi: 10.1055/s-2004-817967.
  72. Cheung NW, Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf). 1997;46(5): 545–9. doi: 10.1046/j.1365-2265.1997.1680985.x.
  73. Wüster C, Steger G, Schmelzle A, Gottswinter J, Minne HW, Ziegler R. Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with ac-romegaly. Horm Metab Res. 1991;23(3): 131–4. doi: 10.1055/s-2007-1003632.
  74. Guth S, Theune U, Aberle J, Galach A, Bam-berger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2012;39(8): 699–706. doi: 10.1111/j.1365-2362.2009.02162.x.
  75. Rogozinski A, Furioso A, Glikman P, Junco M, Laudi R, Reyes A, Lowenstein A. Thyroid nodules in acromegaly. Arq Bras Endocrinol Me-tabol. 2012;56(5): 300–4. doi: http://dx.doi. org/10.1590/S0004-27302012000500004.
  76. dos Santos MC, Nascimento GC, Nascimen-to AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, dos Santos Faria M. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary. 2013;16(1): 109–14. doi: 10.1007/s11102-012-0383-y.
  77. Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary. 2014;17(4): 299–306. doi: 10.1007/s11102-013-0501-5.
  78. Ruchala M, Skiba A, Gurgul E, Uruski P, Was-ko R, Sowinski J. The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol Lett. 2009;30(3): 382–6.
  79. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer. 1998;79(2): 202–11. doi: 10.1002/ (SICI)1097-0215(19980417)79:23.0.CO;2-B.
  80. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology. 2001;142(2): 767–77. doi: 10.1210/endo.142.2.7936.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2017 Chikh I.D., Trigolosova I.V., Dreval' A.V., Trigolosov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies